Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 - … stop work order is lifted, does Vaxart have access to the full $460.7 million award amount? a.   No. The award is … the current share price does not accurately reflect the full value of its oral pill vaccine platform and product … stop work order is lifted, does Vaxart have access to the full $460.7 million award amount? a.   No. The award is …
News

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 - … study with the goal of publishing our findings once the full study analysis is complete. Going forward, we intend to … the preclinical studies in a peer-reviewed forum when the full study analysis is complete. Chief Financial Officer … study with the goal of publishing our findings once the full study analysis is complete. Going forward, we intend to …

Quarterly Results

… section Q4 Vaxart Provides Business Update and Reports Full Year 2025 Financial Results Press space to expand and … section Q4 Vaxart Provides Business Update and Reports Full Year 2024 Financial Results Press space to expand and … section Q4 Vaxart Provides Business Update and Reports Full Year 2023 Financial Results Press space to expand and …
News

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

March 20, 2025 - … Vaxart Provides Business Update and Reports Full Year 2024 Financial Results Vaxart Provides Business Update and Reports Full Year 2024 Financial Results March 20, 2025 Earnings … its business update and financial results for the full year 2024. “Since our founding, Vaxart has been on a …
News

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

March 13, 2025 - … Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 Vaxart to Host Full Year 2024 Business Update and Financial Results … a business update and report financial results for the full year ended December 31, 2024 after the market close on …
News

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

December 2, 2024 - … previously immunized against COVID-19 infection. The full Phase 2b trial will measure efficacy for symptomatic and … previously immunized against COVID-19 infection. The full Phase 2b trial will measure efficacy for symptomatic and … previously immunized against COVID-19 infection. The full Phase 2b trial will measure efficacy for symptomatic and …
News

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

September 30, 2024 - … as well as including at least 25% over the age of 65. The full Phase 2b trial will measure efficacy for symptomatic and … as well as including at least 25% over the age of 65. The full Phase 2b trial will measure efficacy for symptomatic and … as well as including at least 25% over the age of 65. The full Phase 2b trial will measure efficacy for symptomatic and …

Press Releases

News

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

March 14, 2024 - … Vaxart Provides Business Update and Reports Full Year 2023 Financial Results Vaxart Provides Business Update and Reports Full Year 2023 Financial Results March 14, 2024 Earnings … its business update and financial results for the full year 2023. “We are excited to welcome Steve Lo as …
News

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

March 7, 2024 - … Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 Vaxart to Host Full Year 2023 Business Update and Financial Results … a business update and report financial results for the full year ended December 31, 2023 after the market close on …
Scroll to Top